argenx SE - ADR - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH

Ticker Exchange SIC # Website Latest Ticker
ARGX Nasdaq 8731 https://www.argenx.com/

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for argenx SE - ADR

argenx Data Highlight Evidence that VYVGART and VYVGART Hytrulo Drive Transformative Outcomes for Patients with Debilitating Autoimmune Disease - Apr 16th, 2024 5:00 am
Here’s Why argenx SE (ARGX) Pulled Back 23% in Q4 - Mar 29th, 2024 8:42 am
argenx Advances Clinical Development of Efgartigimod in Primary Sjogren’s Disease - Mar 27th, 2024 6:00 am
argenx Announces Annual General Meeting of Shareholders on May 7, 2024 - Mar 26th, 2024 8:00 pm
argenx Announces Approval of VYVGART (efgartigimod alfa) in Japan for Adults with Primary Immune Thrombocytopenia - Mar 26th, 2024 6:00 am
Why Argenx's (ARGX) Stock Price Moved Up 11% on Thursday - Mar 22nd, 2024 2:28 pm
Argenx (ARGX) Moves 11.2% Higher: Will This Strength Last? - Mar 22nd, 2024 11:47 am
Argenx, Immunovant Soar — As Tourmaline Plummets — On A Rival's Lackluster Test Results - Mar 21st, 2024 8:45 pm
Reasons to Invest in argenx (ARGX) - Mar 19th, 2024 11:16 am
argenx Delivers on Promise to Transform Patient Expectations in Autoimmunity at American Academy of Neurology 2024 Annual Meeting - Mar 7th, 2024 9:01 pm
Ascendis Pharma A/S (ASND) Faced R&D Setbacks in Q4 - Mar 7th, 2024 1:14 pm
Should You be Confident in Your Investment in argenx SE (ARGX)? - Mar 7th, 2024 12:28 pm
argenx SE (NASDAQ:ARGX) Q4 2023 Earnings Call Transcript - Mar 1st, 2024 3:12 pm
argenx Reports Full Year 2023 Financial Results and Provides Fourth Quarter Business Update - Feb 29th, 2024 6:00 am
Is a Surprise Coming for argenx (ARGX) This Earnings Season? - Feb 28th, 2024 1:38 pm
argenx to Present at Upcoming Investor Conferences - Feb 26th, 2024 6:00 am
Argenx Is Tracking Well Above the Industry - Feb 22nd, 2024 1:00 pm
argenx to Report Full Year 2023 Financial Results and Fourth Quarter Business Update on February 29, 2024 - Feb 22nd, 2024 6:00 am
3 Biotech Stocks That Could Be Multibaggers in the Making: February Edition - Feb 22nd, 2024 3:08 am
argenx Announces FDA Acceptance of Supplemental Biologics License Application with Priority Review for VYVGART Hytrulo in Chronic Inflammatory Demyelinating Polyneuropathy - Feb 20th, 2024 6:00 am